Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Short-term Investments (2021 - 2025)

Historic Short-term Investments for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $42859.0.

  • InMed Pharmaceuticals' Short-term Investments fell 79.62% to $42859.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $42859.0, marking a year-over-year decrease of 79.62%. This contributed to the annual value of $43384.0 for FY2025, which is 74.31% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Short-term Investments stood at $42859.0, which was down 79.62% from $43384.0 recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Short-term Investments peaked at $46098.0 during Q1 2022, and registered a low of $40582.0 during Q1 2025.
  • For the 5-year period, InMed Pharmaceuticals' Short-term Investments averaged around $43445.5, with its median value being $43085.0 (2024).
  • As far as peak fluctuations go, InMed Pharmaceuticals' Short-term Investments skyrocketed by 327.27% in 2023, and later tumbled by 826.55% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Short-term Investments (Quarter) stood at $45424.0 in 2021, then decreased by 5.22% to $43053.0 in 2022, then increased by 3.27% to $44462.0 in 2023, then decreased by 8.27% to $40787.0 in 2024, then increased by 5.08% to $42859.0 in 2025.
  • Its Short-term Investments stands at $42859.0 for Q3 2025, versus $43384.0 for Q2 2025 and $40582.0 for Q1 2025.